Sign in →

Test Code CITR2 Citrate Concentration, Random, Urine


Specimen Required


Only orderable as part of a profile. For more information see CITRA / Citrate Excretion, Random, Urine.

 

Patient Preparation: Any drug that causes alkalemia or acidemia may be expected to alter citrate excretion and should be avoided, if possible. The patient must avoid laxative use for24 hours prior to collection.

Supplies: Sarstedt 5 mL Aliquot Tube (T914)

Container/Tube: Plastic, 5-mL tube

Specimen Volume: 4 mL

Collection Instructions:

1. Collect a random urine specimen.

2. No preservative.


Secondary ID

606637

Useful For

Diagnosing risk factors for patients with calcium kidney stones

 

Monitoring results of therapy in patients with calcium stones or renal tubular acidosis

Method Name

Only orderable as part of a profile. For more information see CITRA / Citrate Excretion, Random, Urine. 

Reporting Name

Citrate Concentration, Random, U

Specimen Type

Urine

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Urine Refrigerated (preferred) 14 days
  Frozen  14 days

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Clinical Information

Urinary citrate is a major inhibitor of kidney stone formation due in part to binding of calcium in urine. Low urine citrate levels are considered a risk for kidney stone formation. Several metabolic disorders are associated with low urine citrate. Any condition that lowers renal tubular pH or intracellular pH may decrease citrate (eg, metabolic acidosis, increased acid ingestion, hypokalemia, or hypomagnesemia).

 

Low urinary citrate is subject to therapy by correcting acidosis, hypokalemia, or hypomagnesemia by altering diet or using drugs such as citrate and potassium.

Reference Values

Only orderable as part of a profile. For more information see CITRA / Citrate Excretion, Random, Urine.

 

No established reference values

Interpretation

A low citrate value represents a potential risk for kidney stone formation/growth. Patients with low urinary citrate and new or growing stone formation may benefit from adjustments in therapy known to increase urinary citrate excretion.

 

Very low citrate levels suggest investigation for the possible diagnosis of metabolic acidosis (eg, renal tubular acidosis).

 

For children ages 5 to 18, a ratio of less than 0.176 mg citrate/ mg creatinine is below the 5% reference range and considered low.(1)

Method Description

Citric acid in the presence of zinc(2+) at pH 8.2 is catalyzed to oxaloacetate by the enzyme, citrate lyase. Oxaloacetate in the presence of malate dehydrogenase and reduced nicotinamide adenine dinucleotide (NADH) is reduced to malate (II). The citric acid concentration in the reaction mixture can be determined by measuring the disappearance of the light-absorbing NADH.(Delaney MP, Lamb EJ: Kidney disease. In: Rifai N, Horvath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018:1309-1310)

Day(s) Performed

Monday through Saturday

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

82507

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CITR2 Citrate Concentration, Random, U 2128-7

 

Result ID Test Result Name Result LOINC Value
CITR2 Citrate Concentration, Random, U 2128-7